ABMD News and Press, ABIOMED Inc. From 04/04/22

Medical device maker, Abiomed (ABMD -3.6%) is in the red after the company announced the retirement of its Chief Operating Officer and Senior Vice President David Weber, after a 15-year tenure. Mr. Weber informed his decision on March 28, the company disclosed in a regulatory filing. After th...

Abiomed, Inc . (NASDAQ: ABMD) today announced that it will host an investor call on Impella ECP on March 29, 2022 from 4:00 p.m. – 5:00 p.m. EDT. The event will include presentations from circulatory support leader, Dr. Amir Kaki, interventional cardiologist and director of m...

The decline from September 2021 in Medical Device stocks was healthy. Similar price structures provide confidence in coming upside. Boston Scientific is a chart that we are much more enthused about. For further details see: Riding The Stock Waves: Update On The Medical D...

Abiomed, Inc . (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the SVB Leerink 11 th Annual Global Healthcare Conference (virtual...

Abiomed, Inc. (ABMD) Q3 2022 Earnings Conference Call February 03, 2022, 08:00 AM ET Company Participants Nicole Nath - Manager, Investor Relations Mike Minogue - Chairman, President and Chief Executive Officer Todd Trapp - Vice President and Chief Financial Officer Conference Call Participan...

The following slide deck was published by Abiomed, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Abiomed, Inc. 2022 Q3 - Results - Earnings Call Presentation

Abiomed press release (NASDAQ:ABMD): Q3 Non-GAAP EPS of $1.13 beats by $0.16. Revenue of $261.18M (+12.7% Y/Y) beats by $9.71M. The company is increasing the lower end of its fiscal year 2022 revenue guidance to a range of $1,025 million to $1,030 million with growth of 21% - 22% versus prior...

Increasing Low End of Guidance: $1,025 Million - $1,030 Million, up 21% - 22% ABIOMED, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced financial results for the quarter ended December 31, 2021. Q3 financial summar...

Abiomed (NASDAQ:ABMD) is scheduled to announce Q3 earnings results on Thursday, February 3rd, before market open. The consensus EPS Estimate is $0.97 (-5.8% Y/Y) and the consensus Revenue Estimate is $251.47M (+1.4% Y/Y). Over the last 2 years, ABMD has beaten EPS estimates 88% of the time an...

Abiomed, Inc . (NASDAQ: ABMD) announced that on Thursday, February 3, 2022, the Company will release financial results for the third quarter of the fiscal year 2022. The Company will host a conference call to discuss the results on Thursday, February 3, 2022 at 8:00 a.m. ET. Michael...